The impact of CFTR modulator triple therapy on type 2 inflammatory response in patients with cystic fibrosis

BACKGROUND: Treatment of cystic fibrosis (CF) has been revolutionized by the use of cystic fibrosis transmembrane conductance regulator (CFTR) protein modulators such as elexacaftor/tezacaftor/ivacaftor (ETI) triple therapy. Prior studies support a role for type 2 (T2) inflammation in many people wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Mehta, A. M., Lee, I., Li, G., Jones, M. K., Hanson, L., Lonabaugh, K., List, R., Borish, L., Albon, D. P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391773/
https://www.ncbi.nlm.nih.gov/pubmed/37525180
http://dx.doi.org/10.1186/s13223-023-00822-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391773/
https://www.ncbi.nlm.nih.gov/pubmed/37525180
http://dx.doi.org/10.1186/s13223-023-00822-2

Ejemplares similares